|UFDC Home||myUFDC Home | Help|
This item has the following downloads:
1 ITH LYMPHOMA DEPENDENT PRODUCTION OF ANTI RO52 AUTOANTIBODIES By ROBERT CAPEL LYONS A THESIS PRESENTED TO THE GRADUATE SCHOOL OF THE UNIVERSITY OF FLORIDA IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF MASTER OF SCIENCE UNIVERSITY OF FLORIDA 2007
2 2007 Robert Capel Lyons
3 To all who supported me during my research
4 ACKNOWLEDGMENTS It is with sincere gratitude and thanks that I acknowledge the following individuals for th eir contribution to both my professional and personal life which have made this project possible. Whether through technical assistance, intellectual help, or continued words of encouragement, I am truly grateful for the help of the following individuals. First I thank my mentor, Dr. Westley Reeves for his years of support, encouragement, and guidance which have helped shape me both professionally and personally. It is hard to believe that it has been almost seven years since I began as an undergraduate. This experience ignited my passion for research and has undoubtedly impacted my scientific career. I also wish to thank Dr. Minoru Satoh for his years of patience, understanding, and guidance. He has taught me the art of technique from experimental desi gn through implementation and I am truly grateful for all of his assistance over the years. In addition to intellectual and technical assistance, I wish to thank Dina Nacionales, Kindra Kelly Scumpia, Pui Lee, Jason Weinstein, and Haoyang Zhuang for helpi ng make my research career truly enjoyable. To them and everyone else who has been a part of laboratory over the years, I thank you for your contributions to my work and for helping me feel part of a family. I would also like to thank my committee, Dr Edw ard Chan and Dr Ammon Peck. I am truly fortunate to have been able to learn from leaders in the field of autoimmunity. I am also grateful to Joyce Conners for helping me never forget a deadline and her encouragement through the low points. Lastly I wo uld like to thank my mother, father and sister for their constant support and understanding during my research. I especially wish to thank my mother and sister for teaching me how to overcome adversity and never let an obstacle stand in the way of my drea ms.
5 TABLE OF CONTENTS page ACKNOWLEDGMENTS ................................ ................................ ................................ ............... 4 LIST OF TABLES ................................ ................................ ................................ ........................... 7 LIST OF FIGURES ................................ ................................ ................................ ......................... 8 ABSTRACT ................................ ................................ ................................ ................................ ... 10 CHAPTER 1 INTRODUCTION ................................ ................................ ................................ .................. 11 Clinical Aspects ................................ ................................ ................................ ...................... 11 Pathology ................................ ................................ ................................ ................................ 12 ................ 14 An ti Ro60 (SS A), Anti Ro52 and Anti La (SS B) Autoantibodies ............................... 15 Rheumatoid Factor ................................ ................................ ................................ .......... 16 Anti Muscarinic Receptor Autoantibodies ................................ ................................ ...... 17 Polyclonal Hypergammaglobulinemia ................................ ................................ ............ 18 Autoantibody Production ................................ ................................ ................................ ........ 19 P otential Role of Apoptosis in the Generation of Autoantibodies ................................ .. 19 Altered Self Peptides and Autoantibody Production ................................ ....................... 20 Lymphoid Neogenesis: A Possible Site of Autoantibody Production ............................. 21 Links Between Autoimmunity and B Cell Neoplasia ................................ ............................. 23 Antigen Specificity of Extranodal B Cell Neoplasms ................................ ............................ 25 2 MATERIALS AND METHOD S ................................ ................................ ........................... 27 Analysis of Autoantibodies by Immunoprecipitation ................................ ............................. 27 Expression and Purification of Recombinant Autoantigens ................................ ................... 27 ELISA ................................ ................................ ................................ ................................ ..... 28 Anti Ro60, Ro52, and La ELISAs ................................ ................................ .................. 28 Rheumatoid Factor ELISA ................................ ................................ .............................. 28 Anti dsDNA ELISA ................................ ................................ ................................ ........ 29 Purification of Genomic DNA ................................ ................................ ................................ 29 Expression of Recombinant Antibody ................................ ................................ .................... 30 Flow Cytometry ................................ ................................ ................................ ...................... 31 3 CASE REPORT ................................ ................................ ................................ ...................... 32 4 RESULTS ................................ ................................ ................................ ............................... 37 Selective Reduc Ro52 After Excision of Lymphoma ................................ 37 Identification of Lymphoma Heavy and Light Chains ................................ ........................... 38 Lymphoma Bears a Mutat ed V3 7 H Chain ................................ ................................ ........... 38
6 Expression of Recombinant Lymphoma B cell Antigen Receptor ................................ ........ 38 5 DISCUSSION ................................ ................................ ................................ ......................... 47 H chain from the Lymphoma Shows Evidence of Antigen Selection ................................ .... 47 Possible Role of the Tumor in Stimulating Autoantibody Production ................................ ... 49 6 CONCLUSION AND FUTUR E AIMS ................................ ................................ ................. 52 REFERENCES ................................ ................................ ................................ .............................. 54 BIOGRAPHICAL SKETCH ................................ ................................ ................................ ......... 65
7 LIST OF TABLES Table page 1 1 Heavy chain gene usage among MALT lymphomas ................................ ......................... 26
8 LIST OF FIGURES Fig ure page 3 1 P ................................ ................................ ............................ 34 3 2 Imaging and pathology of right paroti d mass ................................ ................................ .... 35 3 3 Flow cytometry of cells isolate d cells from the parotid mass ................................ ............ 36 4 1 Temporal relationship of anti Ro52 autoantibodies to the prese nce of B cell lymphoma ................................ ................................ ................................ .......................... 40 4 2 Levels of other serum autoantibodies over time ................................ ............................... 41 4 3 Identification of the heavy and light cha ins expressed by the lymphoma (PCR) .............. 42 4 4 Nucleotide and amino acid sequences of lymphoma heavy and light chains .................... 43 4 5 SDS PAGE of recombinant antibody ................................ ................................ .............. 45 4 6 Tumor immunoglobulin lacks speci ficity for common autoantigens ................................ 46
9 LIST OF ABBREVIATIONS AE CC American European consensus criteria AQP Aquaporin BAFF B cell activating factor EBV Epstein Barr virus FO Follicular B cell GC Germinal center HCV Hepatitis C virus MZ Marginal zone B cell MZL Marginal zone lymphoma MALT Mucosal associated lymphoid ti ssue M 3 R Muscarinic type 3 receptor MESA Myoepithelial sialadenitis NHL Non PBMC Peripheral blood mononuclear cell pSS PKR Protein kinase receptor RF Rheumatoid factor S HM SS Somatic hypermut ation TD Thymus dependent antigen TI Thymus independent antigen V H Variable heavy region V L Variable light region
10 Abstract of Thesis Presented to the Graduate School of the University of Florida in Partial Fulfillment of the Requirements f or the Degree of Master of Science SYNDROME WITH LYMPHOMA DEPENDENT PRODUCTION OF ANTI RO52 ANTIBODIES By Robert C apel Lyons December 2007 Chair: Westley H Reeves Major: Medical Sciences Marginal zone B cell lymphomas from gastric tissue and s alivary glands are thought to derive from antigen driven responses. However, the target antigens are mostly unknown. Here we report a patient with extranodal marginal zone lymphoma arising in the parotid gland in whom a marked and highly specific increase in anti Ro52 antibodies was seen at time of tumor diagnosis followed by a significant decrease following tu mor excision. There was no change in the levels of anti Ro60 /SS A or anti La /SS B autoantibodies or rheumatoid factor over the same period. Both t he tumor and the increasing/decreasing anti Ro52 antibodies expressed light chain. The patient used a VH3 7 heavy chain that showed evidence of somatic hypermutation and an unmutated V III (A27) light chain. Although this light chain is utilized by rhe umatoid factors, the expressed/reassembled lymphoma heavy and light chains did not have either rheumatoid factor activity or specificity for the Ro52 antigen. Reactivity with other self antigens also was not seen. The data suggest that the presence of the B cell lymphoma was driving the production of anti Ro52 autoantibodies, most likely by providing a source of antigen.
11 CHAPTER 1 INTRODUCTION In 1933 the Swedish ophthalmologist Henrik Sjgren described his clinical and histological findings of xerostomia and keratoconunctivitis sicca among a female c ohort of patients (1) This and is a c hronic autoimmune disease characterized by a progressive mononuclear infiltration of the exocrine glands that primarily affects women at a female to male ratio of 9:1. The disease can occur at any age, with a peak incidence between 40 50 years of age (2) F or a diagnosis of (AEC C) (3) The AECC classification criteria uses cli nical symptoms (dry eyes and mouth), histopathology (lymphocytic infiltrations of salivary gland), and the production of autoantibodies to Ro (SS A), La (SS Clinical Aspects y itself (primary SS) or in conjunction with other autoimmune diseases such as systemic lupus erythematosus or rheumatoid arthritis (secondary SS) (2) The primary clinical symptoms of SS are dry eyes (keratoconjunctivitis sicca) and dry mouth (xerostomia). wetness at 5 minutes is considered diagnostic). Rose Bengal staining can also be performed to identify corneal abrasions, a common complication of keratoconjunctivitis sicca. Oral dryness is manifested by decreased salivary flow, which can also be measured and a ml/15 from glandular tissue destruction via an autoimmune exocrinopathy but also by a disruption in the cascade of saliva production. Inhibition of neuronal inne rvation, aquaporin destruction, and
12 cytokine influence has all been suggested to contribute to the pathogenesis of this disease. In addition to keratoconjunctivitis sicca and xerostomia, a wide variety of extraglandular symptoms of primary SS have been re ported, including Raynaud's phenomenon, chronic nonerosive polyarthritis, arthralgias, interstitial nephritis, renal tubular acidosis, peripheral neuro pathy, demyelinating disease, c r y oglobulinemia, dry cough, interstitial lung disease and lymphoma (2) Elevated risk of marginal zone B cell lymphoma, most commonly of the mucosa associated lymphoid tissue (MALT) type, is a particularly important extraglandular manifestation of rst recognized in 1964 (4) The risk of developing lymphoma is 16 45 fold higher in patients with primary SS than in the general population (5) Pathology infiltration of the lachrymal and sali vary glands. The cellular population of the infiltrates is comprised mainly of T cells (75 85%), but also contains B cells (5 10%) dendritic cells and, later in the disease, plasma cells (6) In contrast, healthy salivary gland tissue is devoid of such lymphocytic infiltrations. The T cell infiltrate in the salivary gland s of SS patients are predominately of the CD4 + phenotype. The ratio of CD4 + to CD8 + T cells is usually about 3:1 (6) These mature T cells + suggestive that they are memory/inducer cells. These infiltrating T cells also express increased levels of adhesion molecules, such as L selectin, which may have important implications in t he sustained inflammatory environment seen in the salivary gland (7) In adults, B cel ls are generated in the bone marrow and migrate to the periphery where they mature at secondary lymphoid organs. Survival of immature B cells in the periphery is dependent upon specific cellular interaction and cytokine influence There are several subse ts of
13 B cells in humans including B 1, follicular (FO) and marginal zone (MZ). B 1 cells reside in the peritoneum and represent the main source of natural antibody production. These cells respond to antigens without the need for T cell help (thymus inde pendent, TI) and show little to no evidence of class switching or somatic hypermutation of their immunoglobulins (8) Follicular, also known as B 2, B cells are the traditional B cells that differentiate into memory or plasma cells upon T cell activation (thymus dependant, TD) and stimulation F ollicular B cells develop from transitional B cells and reside in the follicles of secondary lymphoid organs and participate in both T cell dependant and T cell independent immune responses. F ollicular B cells are IgD high IgM lo CD23 + CD1 lo (9) Upon activation, FO B cel ls enter a germinal center where they undergo affinity maturation and s omatic hypermutation. Marginal zone B cells, which also develop from transitional B cells, reside in the marginal zone of the spleen, surround germinal centers and in humans, recircula te. Marginal zone B cells are able to respond to both TI and TD antigens (9) The marginal zone B cell subset is of particula r importance in patients with SS due to their increased risk of marginal zone lymphomas. Marginal zone B cells are so named because they are located extrafollicularly in secondary lymphoid organs and are IgM high IgD lo CD21 + CD1 + CD5 CD10 and CD2 3 (10) MZ B cells can be further divided based upon the presence or absence of surface IgD. IgM + only MZ B cel ls are primarily TI responders and have unmutated V H immunoglobulins. IgM high IgD lo MZ B cells, also known as memory B cells due to the presence of CD27, have mutated V H immunoglobulins and respond to TI antigens and TD antigens (9) Evidence that MZ B cells have mutated V H genes suggests that these B cells are either post GC B cells that now reside in the marginal zone, or the y have undergone an antigen independent mutation of their V H genes. While the latter is a departure from standard beliefs of B cell somatic hypermutation, it would
14 explain the findings of IgM + CD27 + memory cells found in patients with X linked hyper IgM syndrome (a condition where B cells lack CD40 and are not activated by T cells and there is no germinal center formation (8) The ability of MZ B cells to respond to both TI and TD antigen s allows them to participate in germinal center reactions and could be a subset responsible for the production of autoantibodies. The B cell population of the lymphocytic infiltrates in SS can be divided into CD20 + B cells and the CD38 + /CD27 + plasma/memor y cells (6) The infiltrating B cells of the salivary gland may home t o the tissue in response to increased levels of B cell activating factor (BAFF) expressed by the infiltrating T cells or endothelial cells (11) B cell activating factor is an important B cell survival signal required for the persistence of B cells in tissue that can also help transform transition al type I B cells to transitional type II cells. These CD20 + CD21 + IgM + IgD + B cells may then differentiate into marginal zone or follicular lymphocytes (12, 13) This mechanism may allow for the activation and differentiation of na ve alloreactive cells in the ectopic tissue of the salivary gland under the direction of T cell stimulation, proinflamatory cytokines and BAFF resulting in the production of autoantibodies (14) Interestingly, MZL rarely disseminate from their location of origin, one reason may be due to local BAFF expression. The stimulation of B cells by BAFF may be responsible for their persistence in extranodal locations, and lack of this signal outside of the inflammatory site could result in apoptosis. Autoantibodies and Other Immunological Abnormalities in S S yndr ome membrane bound proteins. Anti Ro (SS A) and anti La (SS B) antibodies, rheumatoid factor (RF) (anti immunoglobulin antibodies), antinuclear antibodies, anti musc arinic receptors and an overall hypergammaglobulinemia are several clinically important self antigens to which many
15 patients with SS mount an immune response (2, 15, 16) Although hepatitis C and HIV infection like pathological picture autoantibody production (e.g. anti Ro/SS A and La/SS B) is very rare in virally induced sicca syndrome (17, 18) These autoantibodies may be prese nt as early as 10 years before the clinical presentation of disease (19) Anti Ro60 (SS A), A nti Ro52 and A nti La (SS B) A utoant ibodies Anti Ro60 (SS A), anti Ro52 and anti La (SS B) autoantibodies are used clinically as a addition to being associated with sicca symptoms, autoantibodies t o Ro60, Ro52 and La are linked with congenital heart block in neonates (20) Antibodies against Ro60 kDa occur in 50 90% of patients with SS (21) Ro60 (SS A) is associated as a protein non coding cytoplasmic RNAs which are tra nscribed by RNA polymerase III (22) The function long double stranded stem structure, where Ro 60 binds, and a loop structure The function of Ro60 is to bind to misfolded, defective, small RNAs which are eventually degraded (23) Approximately 25% of SS patients have anti La antibodies (24) The concentration of La protein is nearly 50 fold higher in the cell than Ro52 and Ro60 (25) La associates with newly synthesized RNA polymerase III transcripts, includi (26) In addition, La binds to newly transcribed Y RNA (23) A DNA RNA unwinding activity has also been obse rved for the La protein and an ability to inhibit the activation of the interferon inducible protein kinase (PKR) has also been shown (27) The 52 kDa Ro antigen (Ro52) is recognized by autoantibodies in sera from many patients (28) Although autoantibodies from patients with SLE and SS can bind
16 to both Ro52 and Ro60, Ro52 is a st ructurally distinct protein whose physical interaction with Ro60 h as not been conclusively shown (23) The Ro52 kd ribonucleoprotein has 2 zinc finger motifs located at its N terminus and a leucine zipper domain located in the central region of the protein (29) Zinc finger domains are important for DNA and RNA binding while leucine zipper domains are important for protein protein in teractions and dimer formation (30) These domains 8 and its ability to act as a transcription factor. In experiments, an increase expression of cellular Ro52 lead to a decrease in cell growth and induced ce ll death in cell culture (31) Ro52 has also been shown to be interferon inducible and associates with IRF 8 which enhances cytokine expression in ma crophages (32) Several monoclonal antibodies directed against Ro52, isolated from pSS patients, have b een produced by EBV/hybridoma These antibodies showed a biased use of VH3 immunoglobulin heavy chain as well as mutations in the CDR regions (20) Interestingly, p syndrome and SLE have an increased expression of Ro52 in PBMCs (31) This abnormal increase in Ro52 expression may account for the presence of anti Ro52 antibodies found in these patients. Rheumatoid F actor Rheumatoid factor is one of the most common autoantibodies found in patients with 80% of primary SS patients. Rheumatoid factor is directed against antigenic determinants on the Fc region of human immunoglobulin and may be of the IgM (most comm o n), I gG, or IgA isotype (15, 33) Rheumatoid factor is also seen in other autoimmune diseas es such as RA and SLE (15) Rheumatoid factor antibodies were origin ally discovered in patients with rheumatoid arthritis (RA) and are used clinically for diagnosis The presence of RF is frequently encountered in like lymphocytic infil trati on of the salivary glands (18, 34) Rheumatoid arthritis is one of the conditions
17 associated with secondary SS. Rheumatoid arthritis is characterize d by inflammation of the synovium and an infiltration of macrophages, and T and B lymphocytes that form ectopic lymphoid tissue (15, 35) This inflammatory environment and the presence of cellular infiltrates are analogous to those seen in the salivary glands of patients with pSS. Although RF is relatively common in the sera an d saliva of pSS patients, it is also can be found in normal sera, especially following immunizations and is seen in patients wi th chronic infections such as bacterial endocarditis (36) Rheumatoid factors aid in the activation of the classi cal complement pathway for the removal of antigen/antibody complexes post infection. Evidence also shows configuration (37, 38) In RA, rheumatoid factor has been suggested to contribute to the pathogenesis of the disease by forming immune complexes that may activate or interact with Fc receptors (via IgG), leading to an inflammator y response of the synovium. ). Examination of preferential gene usage chain genes. nds of SS light chains, particularly VkA27 (39, 40) In circulating antibodies, use of the VH1, VH4 and VH3 heavy chain gen es are predominantly expressed (15) The role of rheumatoid factor in SS is unknown. Anti Muscarinic Receptor Autoantibodies Salivary secretion is accomplished by cholinergic stimulation of muscarinic type 3 receptors (M 3 R) found on salivary acinar cells. Binding of acetylcholine to M 3 R triggers an increase in [Ca2 + ]. The increase in [Ca 2+ ] in turn activates K + and Cl channels, which drive fluid secretion in acinar cells. Secretion of sa liva cannot occur without the increase in [Ca2 + ]. Antibodies directed against M 3 R have been found in patients with primary SS and have been
18 shown to be pathogenic (14, 41) Infusion of primary SS IgG into Ig null NOD mice caused reversible salivary gland hypofunction (42) It has also been shown that primary SS sera exposed to mouse and human submandibular acinar cells inhibited Ca 2+ mobilization by ~50% (41) This effect was reversible upon the removal of the sera. Anti muscarinic antibodies have also been shown to inhibit the translocation of aquaporins to the plasma membranes (43) Aquaporins are transmembrane proteins involved in water transport through epithelial cells. There are several isoforms of aquaporins (AQP), all of which have specific locations. Mice deficient in AQP 5, located in the apical membrane o f acinar cells, showed a decrease of 65% in their salivary secretion rate compared to wild type mice. Analysis of tears shows that AQP 5 cannot be detected from primary SS patients but is present in normal controls. This is due to acinar cell destruction by the lymphocytic infiltrates. Expression of AQP 1 has been found to be decreased by 38% in salivary glands of SS patients (44) possibly explaining the decrease in salivary flow. The presence of anti M 3 R antibodies alone however, is unable to account for all of Polyclonal Hypergamma globulinemia Patients with SS frequently develop polyclonal hypergammaglobulinemia, a manifestation also seen commonly in other autoimmune diseases and infections (8) Polyclonal hypergam maglobulinemia may be explained, in part, by an increased production of cy tokines such as IL 6 and IL 10 IL 6 is crucial for antibody production and in B cell differentiation. Interestingly, patients with active SS have higher levels of IL 6 secreting c ells in the peripheral blood than non active SS patients (45) This increase in IL 6 could be responsible for an incr ease in autoantibody production which results in the observed active disease state.
19 Autoantibody Production The production of autoantibodies in syndrome is in response to self peptides, the same peptides that are tolerized to in normal individual s. Specific antigens are targeted in SS, e.g. Ro52, La, and interestingly they are only targeted in specific locations such as the salivary gland. The autoantibodies produced show evidence of being antigen driven. Analysis of immunoglobulins isolated f rom SS patients show evidence of somatic hypermutation and clonal variation (20, 46) Within the salivary gland, antigen specific B cells and local production of autoantibodies has been detected (47, 48) Interestingly, examination of immunoglobulin light cha chain among infiltrating B cells in the salivary gland (49) The most looming question in autoimmune disease is how self peptides become immunogenic. Several possibilities ranging from apoptosis to virus involvement could be responsible for the presentation or generation of immunogenic self pe ptides Potential Role of Apoptosis in the Generation o f Autoantibodies During apoptosis, programmed cell death, cells undergo characteristic changes leading to DNA fragmentation and cellular death. Apoptosis occurs as a normal process during development in cell turn over, and in injured cells i.e., damaged or infected cells. Binding of the FAS/FASL stimulates cells to undergo apoptosis. Upon binding, the cell shrinks, develops apoptotic blebs on the surface, and selected proteins are targeted for pro teolytic degradation (50, 51) Several autoantigens, such as Ro52 and La, have been shown to cluster and concentrate within these surface blebs and apoptotic bodies during apoptosis (50) If these apoptotic cells are not cleared by macrophages, the altered and newly accessible self peptides may now be immunogenic, especially when presented in the conte xt of inflammation (51) Although apoptosis is a regular occurrence, massive apoptosis could overwhelm the normal mechanisms which prevent n ecrosis and subsequent antigen presentation. Recent work also suggests that the
20 epithelial cells of the salivary gland can act as non professional antigen presenting cells, possibly presenting self peptides (52) Stimulation of an epithelial cell line with type 1 interferon was shown to upregulate the expression of HLA DR, ICAM 1, VCAM, and co stimulatory molecule CD80. Incubation of IFN stimulated endothelial cells with alloreactive T cells isolated from SS patients lead to a proliferation of alloreactive T cells whereas unstimulated endothelial cells were unable to stimulate induce proliferation (52) This observat ion is important in terms of the cellular environment and interaction that occurs in the salivary gland of SS. The increase in inflammation observed in SS salivary glands could allow resident endothelial cells to incorrectly display self peptides and stim ulate alloreactive T cells, which in turn stimulates B cells and the production of clinically observed autoantibodies. Altered Self Peptides a nd Autoantibody Production There are several conditions and events that can alter self peptides making them immuno genic. Viral proteins can bind to host proteins causing abnormal processing of the latter with presentation of cryptic T cell epitopes. This can lead to antibody responses to the host protein. For example, an autoimmune response can be generated against the p53 tumor suppressor protein when it complexes with SV40 large T antigen which persists after viral clearance (53) This finding suggests that viruses may have an initial role in the development of autoantibodies which persists after viral clearance. The d like lesions in the salivary gland of patients with hepatitis C or HIV infection is consistent with a viral etiology (18, 54) Epstein Barr virus has been proposed, since it can establish latency in the salivary glands and in B cells as well (55) Somatic mutations also could lead to immunogenicity of self antigens. Mutations of p53 in breast cancer can lead to autoa ntibody formation, for example (56, 57) Chromosomal translocations can also create autoantigens with abnormal structure. The resulting fusions proteins can, in some cases, stimulate autoimmunity (58) A number of
21 translocations involving API2 and MALT ( t(11;18)) and the bcl 2 and JH locus (t(14;18)) hav e been reported in salivary gland MALT lymphomas (59) However, it is not known whether any of these autoantigens are involved in translocations. Lymphoid N eogenesis: A P ossib le S ite of A utoantibody P roduction Secondary lymphoid organs are genetically preprogrammed during ontogeny and are located in functionally distinct locations throughout the body. These organs are the locations of lymphocyte maturation. Within these secon dary lymphoid organs are germinal centers, specialized structures that arise during an immune response and aid in affinity maturation and somatic hypermutation of B cell immunoglobulin genes (8) Tertiary lymphoid organs however, arise under environmental influences and are extranodal. Three critical events are shown to be required for the formation of ectopic lymphoid tissue; inflammatory cytokine production ( especially TNF ) lymphoid ch emokine production by stromal cells, and HEV development. Like lymph nodes, ectopic lymphoid tissue can contain germinal centers and follicular dendritic cell networks. B cells within the ectopic lymphoid ti ssue can u ndergo terminal differentiation to pl asma cells which have been detected in the synovium of rheumatoid arthritis and salivary (60, 61) Ectopic lymphoid tissue formation (lymphoid neogenesis) occurs in many other autoimmune diseases as well, including the stomach of H. pylori infection and the liver in hepatitis C infection (62) Interestingly, there is a high incidence of B cell lymphoma in asso ci ation with lymphoid neogenesis (62) This suggests that proliferating B cells in these ectopic tissues may be proliferating in the absence of normal stimulator y requirements, allowing autoreactive B cells to proliferate. Lymphoid N eogenesis in S yndrome A common feature of SS is the presence of ectopic, lymphoid tissue in the salivary glands. Lymphoid follicles are more common in
22 primary SS (69.4%) th an in secondary SS with RA 46% or SLE 23% (63) The higher incidence of ectopic lymphoid tissue may help contribute to the higher incidenc e of lymphoma in pSS by allowing B cells to undergo SHM which could increase the chance of an oncogenic event Cheomkines essential for recruiting B cells, T cells, and antigen presenting cells, including BCA 1 CCL19 (ELC), and CCL21 (SLC), have been fou nd in the salivary glands of SS patients (64, 65) Germinal like structures within the glands contain CD21, CD35 + follicular dendritic cells, CD20 + CD10 CD38 B cells as well as CD20 + CD27 + memory cells (66) H owever, these GC like structures lack the typical presence of centroblasts and centrocytes (12) It has also been shown that th ese ectopic lymphoid tissues produce tissue specific, disease relevant antibodies (66) and that a correlation has been found between ectopic GC formation and autoantibody serum levels (67) Interestingly, patients with SS show a decreased population of CD27 + memory B cells in peripheral blood and an accumulation in the salivary gland comp ared to normal healthy controls and patients with SLE (68) This finding further supports the theory that B cells home to the salivary gland, possibly in response to a locally produced antigen. The homing of lymphocytes may be du e in part to the increased expression of BAFF w ithin these germinal centers (12) The formation o f these GC like structures has been shown to rely on the local expression of BAFF and IFN and a positive correlati on between high levels of BAFF a nd IFN SS have bee n shown (69) More importantly, autoreactive B cells could be escaping apoptosis and negative selection in ectopic lymphoid ti ssue due to the increased expression of BAFF. Consistent with this idea, low apoptosis frequency and increased levels of the anti apoptotic protein BCL (62)
23 Links Between Autoimmunity a nd B Cell Neoplasia Primary SS patients are prone to develop a benign lesion in the salivary gland that is known as myoepithelial sialadenitis (MESA). Prominent fe atures of MESA include a prominent lymphoid infiltrate with reactive germinal centers and lymphoepithelial lesions. These lymphoepithelial lesions are a combination of lymphoid cells and myoepithelial and epithelial cells. A general hyperplasia and thicke ning of th e ducts is also observed (70) As this benign lesion progresses, the ductal lumens become occluded with the formation of epimyoepithelial islands. These epimyoepithelial islands consist o f aggregates of ductal epithelium cells and B cells. The normal salivary gland tissue is steadily replaced by this tissue. An important histological transformational change from MESA to MALT lymphoma is the formation of like or mono cytoid B cells that surround the epimyoepithelial islands. These m onocytoid B cells are nearly identical phenotypically to marginal zone B cells (71) The mechanism behind the progression from MESA to MALT is not full y understood but may be due to continued antigenic stimulation in the salivary gland. Evidence in support of this comes from the detection of a monoclonal expansion of B cells in the salivary gland but with a histologically benign phenotype (70) There is a variable period of time between the identification of MESA and lymphoma, with a reported range of 6 months to 29 years (70) Overall, p atients with primary SS have a 16 45 fold increased risk of developing B cell lymphomas (5) and 85% of these lymphomas are non marginal zone subtype. Extranodal marginal zone B cell lymphoma of the salivary gland is an indolent neoplasm that usually presents with localized disease and does not disseminate rapidly Mucosa associated lymphoid tissue lymphomas usually arise in the MALT that is acquired secondary to infectious or autoimmune conditions such as Helicobacter pylori infection in the rome associated MESA
24 in the salivary gland. The initial precipitating inflammatory event in SS is still unknown. Others have suggested that viruses could be responsible for an oncogenic transformation, similar to the mechanism seen in hepatic carcinoma o r in c ervical cancer (34, 72 74) To date, examination of SS MALT lymphomas have not been able to detect the presence of virus including EBV viral protein LMP, viral nucleic acid of EBV, human herpes virus 8, or human T lymphotropic virus 1 (75) However, the re are several striking similarities between marginal zone lymphomas seen in hepatitis C infected patients and marginal zone lymphomas in SS patients It has been well documented that patients with hepatitis C are at an increased risk for hepatocarcinoma as HCV is hepatotropic, but they also have a 35 fold increased risk of developing non Hodgkins lymphoma (76) Hepatitis C is a lymphot ropic virus and viral genomic DNA has been detected in peripheral B cells (34) further suppo rting a possible role in lymphoma. Both SS and HCV infections share several overlapping symptoms, including sicca and mixed cryoglobulinemia. Of interest is that type II MC and non (18) indicative that th e MC could be a precursor to NHL. Evidence also exists to support an antigen driven event in the oncogenesis during HCV infections. Antiviral treatment in patients with HCV and lymphoma showed a decrease in viral load and tumor regression in 75% of cases (76) The decrease in viral load may be analogous to the eradication of H. pylori both producing a loss of antigenic stimulus followed by tumor regression. In addition, patients with MC and HCV NHL show a biased use of VH1 69 germline sequences (77) Similar usage of heavy chain genes between MZL in SS and HCV patients may be due to the same antigen. While the mechanism behind the progression from mixed cryoglobuinemia to lymphoma is unknown, the process mimics the antigen driven response seen in H. pylori
25 There is evidence that MALT lymphomas cou ld be antigen driven in SS The first is through the analysis of B cell immunoglobulin genes. Several groups have reported a biased use of heavy and light chain genes among pSS B cell MALT lymphoma (78 80) A biased use of VH1 69 and VH3 heavy chains indicate that these lymphomas could be responding to the same antigen in different patients Also, examination of the immunoglobulin rearrangements shows significant mutations in the variable region of the immunoglobulins, especially CDR3 (78 80) This suggests that the B cells have undergone affinity maturation and somatic hypermutation at a germinal center, possibly at the ectopic lymphoid tissue present in the salivary gland, in response to an unknown antige n. Additional evidence suggestive of an antigen driven response is in H. pylori gastric MALT lymphomas where eradication of H. pylori results in a compl ete remission of the lymphoma in 80% of cases (81) Antigen S pecificity o f Extranodal B Cell Neoplasms It is thought that the o ncogenic event that occurs in marginal zone B cell lymphoma is due to a constant presentation of antigens, foreign or self, to B cells leading to continued proliferation. Upon eradication of H. pylori infection, gastric MALT lymphoma regresses, supporting the theory that the lymphoma is antigen driven. Although V H and V L chains of tumor immunoglobulins show evidence of SHM indicative of being antigen driven, recent evidence shows that the MALT tumor immunoglobulins are not directed against H. pylori surface antigens (82) In fact, an extensive array of self and H pylori associated antigens were examined for antigen specificity using recombinantly produced tumor immunoglobulins but none of the examine d immunoglobulins showed specificity for the tested antigens. This observation may be due to H. pylori specific T cells which stimulate autoreactive B cells in the gastric mucosa to proliferate through cytokine production and CD40/CD40L interaction. M arg inal zone lymphomas of the gastric MALT have been shown to proliferate in the presence of T cells
26 specific for H pylori but not in the presence of H. pylori and anti CD40L (83) This reveals a contact dependency of B cells and T cells in this response In further support of an antigen driven response in these lymphomas, patients with hepatitis C and MZL have been treated with antiviral therapy. Treatment with antiviral therapy lowered the viral load and produced a r egression of tumor in a majority of cases (72) Unlike H. pylori a putative antigen has be en postulated to be responsible. It has been shown that recombinantly produced tumor immunoglobulin derived from a HCV NHL showed antigenic specificity towards a hepatitis c viral protein, E2 (84) Since this finding however, no other reports of antigen specificity of lymphoma immunoglobulins in HCV patients has been reported. Unlike MZL in HCV, antigen specificity has not been determined in gastric MALT lymphomas or in SS MZL The similarity of gene usage between MZL in pSS and MZL in HCV but not in gastric MZL support a causative role of HCV in the development of MZL (1). This evidence supports the hypothesis that constant antigen stimulation, albeit different in these examples, can lead to lymphoma. It has been shown that MAL T lymphomas in SS patients exhibit gene rearrangements indicative of affinity matura tion and somatic hypermutation and s ome MALT lymphomas have shown rheumatoid factor reactivity (85, 86) VH Segment Salivary Gland Gastric HCV V1 69 17 1 12 V3 7 5 4 3 V3 11 2 0 0 Other ? 23 8 Table 1 1 Heavy c hain g ene u sage a mong MALT l ymphomas: Examination of published usage of heavy chain genes among salivary g land, gastric, an d hepatitis C virus (HCV) MALT lymphoma.
27 CHAPTER 2 MATERIALS AND METHOD S A wide array of cellular, immunological, and molecular techniques were employed in the course of completing this thesis project. This chapter ou tlines the techniques utilized for the completion of the project, and provides a sufficient degree of detail to facilitate their adaptation and/or replication by other investigators. This chapter highlights general protocols developed by the laboratory for experiments completed during this thesis. Analysis of A utoantibodies by I mmunoprecipitation radiolabeled K562 cell extract and sodium dodecyl sulfate polyacrylamide gel elec trophoresis (SDS PAGE) as described (87) T comparing with anti Ro60 (SS A) and anti La (SS B) prototype sera. Normal human serum and a n irrel evant IgG1 chain recombinant antibody from a chronic lymphocytic leukemia patient (CLL) were used a s negative control s Expression and P urificat ion of R ecombinant A utoantigens Recombinant Ro52, Ro60 /SS A La /SS B were produced as described (28) Briefly, each gene was amplified from cDNA obtained from human peri pheral blood mononuclear cells and cloned into the PET28a expression vector with a n N termin al 6 histidine tag. E. coli BL21 DE3 was transformed with the plasmids and induced to produce fusion protein with 2 mM IPTG After four hours, the bacteria were centrifuged and lysed Th e recombinant proteins were purified using a Ni NTA resin column (Sigma Aldrich, St. Lo uis, MO ) and eluted in 6 M u rea.
28 ELISA Anti Ro60, Ro52, and La ELISAs The wells o f microtiter plates (Immobolizer Amino; Nunc, Nape r ville, IL) were coated with 1 g/ml purified recombinant antigen in borate buffered saline overnight at 4C. Plates were wa shed with TBS Tween 20 after each step and blocked with 0.5% bovine serum albumin (BSA) 150 mM NaCl, 2 mM EDTA, 20 mM Tris pH 7.5, 0.3% Nonidet P 40 (NET/NP40) for 1 hour at room temperature as described (88) Human sera were diluted 1:4000 for the Ro52 and La ELISAs, and 1:500 for the Ro60 ELISA. Antibody binding was detected with goat anti human immunoglobulin antibodies ( chain specific 1:1000 dilution from Southern Biotechnology, Birmingham, AL). The assay was developed using diethanolamine/phosphatase buffer (Sigma Aldrich) and absorbance was determined 405 nm using a VERSA max ELISA plate reader (Molecular Devices). Using serial 1:5 dilutions of high titer anti Ro52 or La antibody positive serum, the absorbance was converted to units using a standard curve. ROC an alysis was used t o determine cut off values for positive sera Optimum sensitivity and specificity were 90% and 80% respectively and the corresponding cut off values for the anti Ro52 and La ELISA s were 2.21 and 1.5 units respectively Samples were consi dered positive for anti Ro60 if the absorbance was higher than the mean of 10 healthy controls + 3 S.D. Rheumatoid F actor ELISA Rabbit IgG (Sigma Aldrich ) was coated on microtiter plates (Nunc) at a concentration of 1 g/ml overnight at 4C. Plates wer e washed with TBS Tween 20 after each step and blocked as above Patient sera and recombinant antibodies were diluted 1:200 in blocking buffer and incubated for 1.5 hours. Goat anti human IgG and IgM were diluted at 1:1000 and incubated for 1.5 hours. S amples were developed as above. Samples were considered positive for rheumatoid factor if the absorbance was higher than the mean of 10 healthy controls + 3 SD.
29 Anti dsDNA ELISA S1 nuclease treated calf thymus DNA (Sigma Aldrich) was coated overnight at 4 C on microtiter plates (Nunc) at a concentration of 3 g/ml in Reacti Bind DNA coating solution (Pierce, Rockford, IL) Patient sera or recombinant antibody were test ed at a 1:500 dilution and incubated for 2 hours at room temperature. Binding was detec ted with goat anti human IgG antibody (1:1000) and the assay was developed as above. High titer anti dsDNA antibody positive serum was us ed to generate a standard curve and the optical readout was converted to units using SoftMax Pro (Molecular Devices, S unnyvale, CA). Purification of G enomic DNA Genomic DNA from biopsy tissue was purified using the Pinpoint Slide DNA Isolation sections of paraffin embedded tissue were washed twice in xylenes at room temperature for 30 min. The sample was then re hydrated for two minutes per step in graded ethanol water solutions (100%, 70%, 50%, and 0% ). The sample was then air d ried and digested with proteinase K for 4 hours at 55 C. The digested product was heated at 96 C for 10 minutes to inactivate proteinase K. The isolated DNA was analyzed on a 1% agarose gel in Tris borate EDTA buffer. Immunoglobulin V D J S equence A nal ysis To determine the VDJ segment usage, 1 l of genomic DNA from the tumor was amplified by PCR For the heavy chain, VH1 7 forward primers were used individually along with a JH consensus reverse primer (89) For light chain, primers (89) Each primer contained a restriction site that permitted cloning of the DNA fragment. The reaction was carried out in a 20 l volume containing a total concentration of 1.25 nM pooled VHF/VLF primers and 2.5 nM JH primers 1X PCR buffer, 1.5 mM MgCl 2 2.5
30 mM dNTPs, and 0.05 units of Taq DNA polymerase (Invitrogen, San Diego, CA). The reaction was carried out with a PTC 100 Programmable Thermal Co ntroller (MJ Research, Inc., Waltham, MA) as follows: initial denaturation at 95C for 12 min, denaturation at 94C for 40 sec, annealing at 60C for 45 sec, and extension at 72C for 45 sec. After 35 cycles, extension was continued at 72C for an addition al 10 min. The V H and V L PCR products, which contained V H D J H or V L J L w ere cloned into a TA vector ( Invitrogen ) and sequenced using an Applied Biosystems Model 373 Stretch DNA Sequencer. Sequenc es were compared against germ line sequences using the Ig Blast Software (NCBI) vectors described previously by Wardemann, et al. (90) Briefly, the amplified DNA fragment and vector were digested with PinAI and SalI for IGHV D J and with AgeI and BsiWI for IGKV J and ligated using T4 DNA ligase. Plasmids were transformed into E. c oli BL21 D E3 and purified using the Qiagen miniprep plasmid purification kit accor s protocol (Qiagen, Valencia, CA) Expression of R ecombinant A ntibody 293T human embryonic kidney fibroblasts were cultured in DMEM (Mediatech, Her n don, VA ) supplemented with 10% fetal bovine serum 4 mM L glutamine and penicillin/ streptomycin. Log phase cells were co transfected with 30 plasmid DNA in 120 l Lipofectamine 2000 (Invitrogen) (91) Cells were grown at 37C for si x days before harvesting the supernatant. Recombinant antibodies were purified using ImmunoPure Immobilized Protein G (Pierce). Immunoglobulin in the cell culture supernatant was quantified using an anti human Ig ELISA (Southern Biotechnology) with from human serum as standard. The purified r ecombinant antibody was adjusted to a concentration of 0.1 mg/ml. Assembly of the H and L chains was verified by purifying the
31 antibodies using protein G Seph arose followed by elution and analysis by SDS PAGE ( C oomassie blue staining and western blot analysis using anti Flow C ytometry A s ingle cell suspension was generated from the salivary gland biopsy specimen by digesting w ith collagenase and analyzed by flow cytometry as described (92, 93) The isolated cells were stained with the following labeled antibodies: anti FITC, anti chain FITC, anti CD19 PE, CD5 FITC, anti CD23 PE, anti CD10 FITC, anti CD19 PerCP Cy5.5, and anti CD20 PE (anti light chain antibodies were from Dako North America, Carpinteria, CA; all others were from BD Biosciences, San Jose, CA ). Isotype controls were used to evaluate background fluorescence. Isolated tumor cells were washed in staining buffer (PBS supplemented with 0.1% NaN 3 and 1% bovine serum albumin). Antibodies were added a t suggested concentra tion s. Cell suspensions were washed twice in PBS before acquiring data on a FACSCalibur f low cytometer (BD Biosciences) and analyzing with FCS Express Version 2 (DeNovo Software, Thornhill, ON, Canada). At least 20,000 events per sample were analyzed usi ng size gating to exclude dead cells.
32 CHAPTER 3 CASE REPORT A 58 year syndrome and right parotid swelling and tenderness. She noted the onset of fatigue, dry eyes, and dry m outh in 1980 and had recurrent bilateral parotid swelling in 1982 3. In 1997 she underwent rheumatological evaluation for parotid swelling, oral, ocular and vaginal dryness, and arthralgias. She was found to have a positive ANA (1:1280 titer, speckled pa ttern), and positive anti Ro60 (SS A) and La (SS globulin level was 4.4 g/dL and she had a white blood cell count of 3600 (25% lymphocytes). A Schirmer test was abnormal. In 2001 she was referred to the Uni versity of Florida with persistent sicca symptoms and intermittent right parotid swelling and tenderness. The presence of anti Ro60 and anti La (SS B) autoantibodies was confirmed by immunoprecipitation (Fig. 3 1A) and high titer anti Ro52 autoantibodies were detected by ELISA (Fig. 3 globulin level was 4.6 g. Serum protein electrophoresis did not show an M spike. The parotid swelling initially responded well to hydroxychloroquine. However, in August 2002, she had recurrent ri ght parotid swelling every 1 2 weeks and in November 2002, the swelling became persistent. A computer guided tomography (CT) scan of the right parotid revealed a 1 cm mass (Fig. 3 2A) and a needle biopsy obtained for flow cytometry showed a predominance o f B light chain but was non diagnostic of lymphoma. An excisional biopsy was performed revealing an encapsulated mass of the right parotid gland (Fig. 3 2B). There was no apparent extension of the tumor outside of the solitary mass. Hema toxylin & eosin staining revealed lymphoepithelial lesions characteristic of an extranodal MALToma (Fig. 3 2C, D). Flow cytometry of cells isolated from the mass again revealed a predominance of CD19 + B 3A). On furthe r analysis, the CD19+ cells were found to be
33 CD5 CD10 CD23 and CD20 + (Fig. 3 3B), consistent with a marginal zone B cell phenotype, confirming the diagnosis of an extranodal marginal zone lymphoma. A CT scan of the chest and pelvis and a bone marrow biopsy did not reveal any additional nodal involvement. Further therapy was not felt to be necessary and the patient has remained free of lymphoma for five years.
34 Figure 3 cells using patient sera, anti La and anti Ro prototype sera, and serum from a normal healthy control (N). B, Anti Ro52 ELISA using recombinant human Ro52 as antigen. Normal human sera (NHS, n = 20) and anti Ro52+ sera (n = 20) were tested at a 1:50 dilu tion. Arrow indicates the result using serum from the patient reported here.
35 Figure 3 2. Imaging and pathology of right parotid mass. A, right parotid gland showing a 1.5 cm mass (arrow). B, Low power hematoxylin & eosin stain C High power hematoxylin & eosin staining showing lymphocytic infiltration and lymphoepithelial lesions characteristic of MALT type B cell lymphoma (arrows).
36 Figure 3 3. Flow cyto B, Staining of CD19+ B cells for CD5 (left) and CD23 (middle) and s taining of B cells for CD20 and CD10 (right). Arrows indicate malignant cell population.
37 CHAPTER 4 RESULTS Selective R A nti Ro52 A fter E xcision of L ymphoma Analysis of serial serum samples revealed an increase in anti Ro52 antibod ies from 275 units before the diagnosis of lymphoma to750 units when lymphoma was diagnosed four months later (Arrows, Fig. 4 1A). Following excision, anti Ro52 antibodies fell to 300 units over the next six months (Fig. 4 1A). Analysis of anti Ro52 light chains showed a striking preferential usage of light chains. 0.8 1.6 over the same time period and was never hi gher than 1.7 (Fig 4 1B). Further analysis of the anti Ro52 antibodies indicated that the anti tumor and decreased after excision (Fig. 4 1C) whereas anti change or even increased slightly after the tumor was removed (Fig. 4 1D). These results raised the possibility that the lymphoma was either driving the immune response to Ro52 or was secreting anti Ro52 autoantibodies. To further assess the specificity of the respons e, rheumatoid factor, anti La and anti Ro60 levels were also examined longitudinally (Fig. 4 2). Although low level rheumatoid factor was levels fell within the n ormal range (Fig. 4 globulin remained essentially unchanged over the period of observation (2001 2004), including the period between 4/02 and 11/02 when the lymphoma developed and was excised (Fig. 4 2A). Similarly, there was little change in anti Ro60 (SS A) antibody levels over this time (Fig. 4 2B). Her low level
38 anti La (SS B) antibodies increased from 14 to 26 units from 4/02 until 8/02, but then increased slightly more to 28 anti La units after surgery (Fig. 4 2C). Toge chain bearing anti Ro52 antibodies specifically increased with the onset of her B cell lymphoma and decreased after it was removed. Consequently, we examined the possibility that the marginal zone lymphoma was p roducing anti Ro52 antibodies. Identification of L ymphoma H eavy and L ight C hains Using purified genomic DNA from the lymphoma, we amplified the immunoglobulin heavy and light chain genes from the malignant B cells. A strong band at ~350 bp was obtained u sing the VH3 forward primer but not with VH 1, 2, 4, 5, 6 primers (Fig. 4 3A). actin primers amplified the expected 490 bp and 297 bp fragments. Further analysis using primers specific for VH3A and VH3B showed that the tumor H chain was VH3A (Fig. 4 3B). The light chain was amplified using V III (forward) and J 2I (rever se) primers, but not with other combinations (Fig. 4 3C). Thus, the tumor expressed a VH3 H chain and a V III L chain. Lymphoma B ears a M u tated V3 7 H C hain The heavy chain aligned with the germline V3 7 sequence (Fig. 4 4, top left). Sequence analysis s howed that it had a total of 12 mutations, 9 within the CDR regions. Two of the 9 CDR mutations were replacement mutations vs. 2 of 3 in the framework regions (Fig. 4 4, top right). The tumor L chain sequence closely matched the germline A27 sequence (Fi g. 4 4, bottom) a member (94) There were two mutations, both in the framewo rk region 3. The CDR 1, 2, and 3 sequences were unmutated (Fig. 4 4, bottom). Expression of R ecombinant L ymphoma B cell A ntigen R eceptor T o determine if the lymphoma B cells had antigen specificity, the immunoglobulin heavy and light chains were inserted into expression vectors that individually express the cloned
39 fragment as an IgG1 heavy light chain (90) Human embryonic kidney cells were transiently co transfected with the heavy and light chain constructs and the recombinant IgG1 an tibody was purified from culture supernatant (Fig. 4 5). The recombinant antibody showed no reactivity with human Ro52 in ELISA. (Fig. 4 6A). To exclude the possibility that low pH used to elute the recombinant antibody inactivated it, we also tested rec ombinant antibody directly from the supernatant (without further purification) and again saw no binding (not shown). We then tested for reactivity with other autoantigens. The antibody showed no reactivity with Ro60 (SS A) (Fig. 4 6B) or with rabbit IgG (RF, Fig. 4 6C). There also was no reactivity with La (SS B) and the U1 A antigen (not shown). The recombinant antibody showed no reactivity with any of the cellular proteins produced by K562 (erythroleukemia) cells by immunoprecipitation (Fig. 4 6D). S imilar negative results were obtained using cell extract from a human salivary gland ductal epithelium cell line (not shown) The possibility that Epstein Barr virus (EBV) is involved in the pathogenesis of SS has been discussed (95, 96) To eliminate EBV as a possible target of the lymphoma B cell receptor (BCR), we performed an immunoprecipitation with radiolabeled B95 8 cells a marmoset cell li ne that sheds EBV The recombinant antibody did not react with either cellular e xtracts or supernatant from B95 8 cells (not shown).
40 Figure 4 1. T emporal relationship of anti Ro52 autoantibodies to the presence of B cell lymphoma. A, Anti Ro52 IgG lev els as a function of the date of serum collection (recombinant anti Ro52 ELISA). B, Ro52 antibodies (ELISA) vs. total serum IgG (ELISA) over time. C, Ro52 antibodies (ELISA); D, nti Ro52 antibodies (ELISA). Note the different Y axis scales in panels C and D. In all panels, arrows indicate the samples immediately before lymphoma was diagnosed, at the time of diagnosis, and after surgical resection of the parotid mass
41 Figure 4 2 Levels of other serum autoantibodies over time. A, Rheumatoid factor ELISA (rabbit IgG antigen); B, anti Ro60/SS A ELISA (recombinant human Ro60 antigen); C, anti La/SS B ELISA (recombinant human La antigen). Arrows indicate the samples immediately be fore lymphoma was diagnosed, at the time of diagnosis, and after surgical resec tion of the parotid mass, as in 4 1
42 Figure 4 3 Identification of the heavy and light chains expressed by the lymphoma (PCR). A, Heavy chain analysis. Tumor DNA was amp lified using VH1, 2, 3, 4, 5, 6, or 7 forward primers along with a JH consensus reverse primer. A 350 bp fragment was actin (control) primers amplified fragments of ~ 490 and 297 bp, respectiv ely (arrows on right). B, Tumor DNA was amplified using forward primers specific for VH3A and VH3B, respectively, along with JH consensus reverse primer. A specific band was amplified by the VH3A primers but not the VH3B primers (arrow). C, Light chain analysis. (arrow).
43 Figure 4 4 Nucleo tide and amino acid sequences of lymphoma heavy and light chains. A. Alignment of the tumor heavy chain with germline VH3 7 nucleotide (left) and amino acid (right) sequences. Positions of the CDR1, CDR2, and CDR3 regions are indicated by boxes. Bottom, Alignment of the tumor light chain nucleotide (left) and amino acid (right) sequences with the germline A27 sequence. Positions of the CDR1, CDR2, and CDR3 regions are indicated by boxes. A
45 Figure 4 5. SDS PAGE of recombinant antibody. SDS PAGE of purified recombinant antibody shows heavy and light chain pairing with correct size of 25 kD and 50 kD.
46 Figure 4 6 Tumor immunoglobulin lacks specificity for common autoantigens. Recombinant antibody was expressed in 293 cells, purified from the culture supernatant, and tested for reactivity with various antigens. A, Anti Ro52 ELIS A. Recombinant antibody concentration of 0.1 mg/ml. Reactivity of human prototype anti Ro52 sera (positive control, n = 10) and normal human sera (NHS, negative control, n = 1 0) are shown on the left. B, Anti Ro60 ELISA. Recombinant antibody (rAb) and a control CLL IgG1 Reactivity of human prototype anti Ro60 sera (positive control, n = 10) and nor mal human sera (NHS, negative control, n = 10) are shown on the left. C, Rheumatoid for reactivity with rabbit IgG. Reactivity of human prototype rheumatoid factor positive se ra (positive control, n = 10) and normal human sera (NHS, negative control, n = 10) are shown on the left. D, Immunoprecipitation using the recombinant antibody. [ 35 S] labeled K562 cell extract was immunoprecipitated with the recombinant antibody (rAb), Ro60 and La positive reference serum (Ref), or normal human serun (NHS).
47 CHAPTER 5 DISCUSSION Extranodal m arginal zone lymphomas are associated with chronic inflammation due to immune or autoi mmune responses in the stomach, thyroid, salivary gland and other locations (97) Antigen stimulation is thought to play a role in the pathogenesis of these tumors, whi ch generally bear B cell receptors that have undergone somatic hypermutation (79, 98 100) G astric lymphomas frequently regress after eradication of H pylori infection, but specificity of the lymphoma cells for H. pylori antigens has not been established (81, 82, 97, 101) It has been suggested t hat lymphoma cell growth is stimulated by H. pylori activated T cells via CD40 CD40L interactions (83, 97) However, t umors producing antibodies that recognize H. pylo ri antigens have not been reported, although marginal zone lymphomas producing rheumatoid factors have been identified (86, 102) In most instances, the antigen/autoantigen specificity of thes e B cell neoplasms and the precise nature of their link with autoimmunity remain to be elucidated. We report a patient with an IgG lymphoma that developed in association with a dramatic and h ighly selective increase in IgG Ro52 anti bodies. When the tumor was surgi cally resected, the anti Ro52 level decreased. At the same time, there was no significant change in the levels of other autoantibodies (anti Ro60 /SS A anti La /SS B L chain bearing anti Ro52 antibodies. Altho ugh suggestive of the possibil ity that the tumor might produce anti Ro52 antibodies, this could not be confirmed using recombinant IgG from the lymphoma H chain from the L ymphoma S hows E vidence of A ntigen S election Analysis of the heavy chain (V3 7) a nd light c
48 extranodal marginal zone lymphomas as well as evidence of antigenic stimulation. The V 3 7 H chain utilized by this patient specific for Ro52 (16, 66) The H chain sequence shows a lesser degree of somatic mutation, especially in the CDR3 re gion, than reported in other marginal zone lymphomas (46, 78 80, 86) However, mutations were concentrated primarily in the CDRs, consistent with the possibility that the malignan t B cells were antigen selected. The VH family utilized most frequently by peripheral blood lymphocytes is VH3 (103) In contra st, MALT lymphoma s of both nodal and extranodal sites most frequently utilize VH4 fo llowed by VH3 and VH1 (104) VH1 and VH3 are used preferentially in MALT lymphoma s originating in the salivary gland (78, 80) and MA LT lymphomas expressing V3 7 have been reported previously (86) VH1 and VH4 are commonly utilized by rheumatoid factor s from patients with Sjgren's syndrome whereas VH3 is more common in rheumatoid arthritis (37, 105, 106) In contrast to the H chain, the L chain from this tumor was in a near germline configuration (Fig. 4 4). Biased use of V A27 L chain by marginal zone lymphomas arising in the salivary glands (79) and both A27 and other family members are frequently utilized in antibodies with rheumatoid factor activity, especially when paired with H chains containing V1 69 and JH4 (78, 86) The P M alignant B cells L ack A utoantigen S pecificity associated with a spectrum of autoantibodies, including those specific for the ribonucleoproteins Ro60 (SS A, consisting of a 60 kDa protein bound to the Y1 4 small RNAs ) and La (SS B, a 45 kDa protein bound to RNA polymerase III precursor products) as well as autoantibodies against the 52 kDa Ro52 antigen, an interferon inducible RING finger protein that interacts with and ubiquitinates the transcription factor interfero n regulatory factor 8 (IRF 8) (32) The production
49 (15) The patient reported here produced high levels of anti Ro60/SS A, anti La/SS B, and anti Ro52 autoantibodies and low levels of rheumatoid factor. crease in serum anti Ro52 activity coincided with the onset of the that the malignant B cells were specific for Ro52. However, recombinant tumor antibody sho wed no reactivity with human Ro52 (Fig. 4 reactive (Fig. 3 1 and data not shown). As the epitopes recognized by antibodies tend to be conformational, it is possible that the recombinant antibody was reactive with an epitope that did not fold correctly when expressed in bacteria. However, this explanation is unlikely if one assumes that the increasing and decreasing levels of anti were due to production of anti Ro52 by the tum or (Fig. 4 1). L chain (A27), we also were unable to demonstrate any rheumatoid factor activity (Fig. 4 5C). Reactivity with the native Ro60/SS A and La (SS B) proteins was not seen either (Fig. 4 5B, D). Thus, although the H chain iso characteristics suggestive of prior antigen exposure we were unable to show specificity for any Possible R ole of the T umor in S timul ating A utoantibody P roduction Analysis of H and L chain sequences suggest that B cells undergo antigen driven clonal (100) B cells reactive with self antigens such as Ro60/SS A and La/SS B have been found within the ectopic lymphoid (48, 107) Similarly, rheumatoid factor B cells have been detected in rheumatoid synovium (35) Also, anti U1 A specific B cells have been localized to ectopic lymphoid tissue in mice with
50 tetramethylpentadecane induced lupus (D Nacionales, et al. Submitted). Along with the antigen specific B cells, antigen specific T cell s home to ectopic lymphoid tissue in close proximity to B cells reactive with the same antigen (J Weinstein, et al. Submitted). In view of the presence of autoreactive B and T cells within ectopic lymphoid tissue, it is intriguing that the formation of l ymphoid structures in various locations (such as salivary gland, synovium, thyroid, liver, or stomach) is associated with the development of a unique and tissue specific spectrum of autoantibodies (108) suggesting that the antigens/autoantigens driving the response could be produced locally within the affected tissues. Thus, the production of ing to the activation of antigen specific but non malignant T and B lymphocytes is potentially an alternative explanation for the data shown in Figures 4 1 and 4 2 In fact, autoimmunity is not unusual in neoplastic diseases such as hepatocellular carcinom a (109, 110) breast cancer (56, 57) lung cancer (111) and acute myeloid leukemia (58) to name a few examples. In some cases, altered structure of the autoantigen through mutation or translocation is strongly implicated in the pathogenesis of the immune response (56 58) Although we do not know whether Ro52 expression was elevated in the lymphoma B cells, there is increased Ro52 expression in peripheral blood mononuclear cells from patients with autoimmune di sease (31) Inc reased Ro52 expression increases ubiquitination of IRF 8, and could enhance the production of IL 12 and Type I interferon, potentially causing an excessive inflammatory response (32) altered B cell differentiation (112) and enhanced maturation of immunostimulatory dendritic cells, which could promote autoimmunity (113) In addition to IL 12 and Type I interferon, other cytokines may have been produced by the lymphoma. Of particular interest is IL 6, a pleiotropic cytokine that plays an important role in
51 the maturation of antibody secreting plasma cells (114) IL 6 is produced by atrial myxomas (115) and also by some marginal zone lymphomas (116) secreting IL 6, it might have stimulated the differentiation of autoantib ody secreting cells, but it is not clear why this would have been selective for anti selectively accumulated Ro52 specific (and not Ro60 or La specific) B cells. Finally, mutations in the Fas gene have been associa ted with both autoimmunity and non Hodgkin lymphoma (117, 118) In one series of 150 patients, Fas mutations were found in 11%, including three extranodal MALT type lymphomas (60%) (117) It is conceivable that the the lymphom a cells (119) The inflammation associated with necrotic tumor death might contribute to the induction of autoimmunity, but again it is unclear why the response should be selective for Ro52. In conclusion, the temporal re lationship between increased production of Ro52 autoantibodies and the presence of an extranodal marginal zone lymphoma as well as the highly selective production of anti Ro52, and not other co existing autoantibodies, suggests that either ymphoma produced anti Ro52 autoantibodies or that its presence somehow stimulated the production of these autoantibodies by non malignant B cells. Our data are most consistent with the latter possibility, but further studies are needed to define the mecha nism by which the lymphoma stimulated anti Ro52 autoantibody production.
52 CHAPTER 6 C ONCLUSION AND FUTURE AIMS syndrome was unable to be determined. The mecha nism behind the observed increase in anti chain specific antibodies was not elucidated through this work. Altered presentation of Ro52, in the environment of inflammation and pro B cell cytokines, by the lymphoma is the most likely candidate for th e observations seen in this patient. While an exhaustive search for foreign and self antigens was conducted, there are still several causative agents which have yet to be excluded. Due to similar immunoglobulin gene rearrangements between marginal zone l ymphomas in hepatitis C infected patients and marginal zone lymphomas in SS, it will be interesting to look for possible antigen specificity against hepatitis C virus, especially since the discovery of a MZL in a patient with HCV which showed reactivity to wards the hepatitis C viral protein E2. In addition, certain translocations have been detected in MZL, particularly of the gastric MALT, and may play a role in their development and pathogenesis. Due to genetic abnormalities found in gastric marginal zon e lymphomas, examination of our tumor for t(11:18) or t(14:18) would be a worthwhile endeavor. In addition, recent work has elucidated the function of Ro52 as an interferon inducible gene which associates with IRF 8. Due to this association, it would be interesting to look for anti IRF8 antibodies in this patient. The only tissue that is available from the tumor is paraffin embedded. This process does not preserve RNA and previous work to obtain RNA of high quality was unsuccessful. However, more rece nt techniques could allow for the isolation of intact RNA from the paraffin embedded tissue. Examination of Ro52 and IL 6 expression levels of the tumor may help illustrate a more complete picture of lymphoma in our patient.
53 s is a rare event, it has been documented. Being vigilant in monitoring for the tumor reemergence in this patient may allow for a more thorough for
54 REFERENCES 1. Mutlu, S., and C. Scully. 1993. The person behind the eponym: Henrik Sjogren (1899 1986). J Oral Pathol Med 22:439. 2. Delaleu, N., R. Jonsson, and M.M. Koller. 2005. Sjogren's syndrome. Eur J Oral Sci 113:101 113. 3. Vitali, C., S. Bomba rdieri, R. Jonsson, H.M. Moutsopoulos, E.L. Alexander, S.E. Carsons, T.E. Daniels, P.C. Fox, R.I. Fox, S.S. Kassan, S.R. Pillemer, N. Talal, and M.H. Weisman. 2002. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American European Consensus Group. Ann Rheum Dis 61:554 558. 4. Talal, N., and J.J. Bunim. 1964. The Development of Malignant Lymphoma in the Course of Sjoegren's Syndrome. Am J Med 36:529 540. 5. Kassan, S.S., T.L. Thomas, H.M. Moutsopou los, R. Hoover, R.P. Kimberly, D.R. Budman, J. Costa, J.L. Decker, and T.M. Chused. 1978. Increased risk of lymphoma in sicca syndrome. Ann Intern Med 89:888 892 6. Larsson, A., A. Bredberg, G. Henriksson, R. Manthorpe, and A. Sallmyr. 2005. Immunohistoc hemistry of the B cell component in lower lip salivary glands of Sjogren's syndrome and healthy subjects. Scand J Immunol 61:98 107. 7. Edwards, J.C., L.S. Wilkinson, P. Speight, and D.A. Isenberg. 1993. Vascular cell adhesion molecule 1 and alpha 4 and b eta 1 integrins in lymphocyte aggregates in Sjogren's syndrome and rheumatoid arthritis. Ann Rheum Dis 52:806 811. 8. Janeway C., T.P., Walport M., Shlomchik M. 2004. Immunobiology: The Immune System in Health and Disease. Garland Publishing, Okford, UK. 800 pp. 9. Dono, M., S. Zupo, M. Colombo, R. Massara, G. Gaidano, G. Taborelli, P. Ceppa, V.L. Burgio, N. Chiorazzi, and M. Ferrarini. 2003. The human marginal zone B cell. Ann N Y Acad Sci 987:117 124. 10. Weller, S., C.A. Reynaud, and J.C. Weill. 2005. Splenic marginal zone B cells in humans: where do they mutate their Ig receptor? Eur J Immunol 35:2789 2792. 11. Lavie, F., C. Miceli Richard, J. Quillard, S. Roux, P. Leclerc, and X. Mariette. 2004. Expression of BAFF (BLyS) in T cells infiltrating labi al salivary glands from patients with Sjogren's syndrome. J Pathol 202:496 502. 12. Daridon, C., J.O. Pers, V. Devauchelle, C. Martins Carvalho, P. Hutin, Y.L. Pennec, A. Saraux, and P. Youinou. 2006. Identification of transitional type II B cells in the salivary glands of patients with Sjogren's syndrome. Arthritis Rheum 54:2280 2288.
55 13. Martin, F., and J.F. Kearney. 2002. Marginal zone B cells. Nat Rev Immunol 2:323 335. 14. Nakamura, H., A. Kawakami, and K. Eguchi. 2006. Mechanisms of autoantibody pr oduction and the relationship between autoantibodies and the clinical manifestations in Sjogren's syndrome. Transl Res 148:281 288. 15. Elagib, K.E., M. Borretzen, R. Jonsson, H.J. Haga, J. Thoen, K.M. Thompson, and J.B. Natvig. 1999. Rheumatoid factors i n primary Sjogren's syndrome (pSS) use diverse VH region genes, the majority of which show no evidence of somatic hypermutation. Clin Exp Immunol 117:388 394. 16. Elagib, K.E., P. Tengner, M. Levi, R. Jonsson, K.M. Thompson, J.B. Natvig, and M. Wahren Her lenius. 1999. Immunoglobulin variable genes and epitope recognition of human monoclonal anti Ro 52 kd in primary Sjogren's syndrome. Arthritis Rheum 42:2471 2481. 17. Geier, S.A., S. Libera, V. Klauss, and F.D. Goebel. 1995. Sicca syndrome in patients inf ected with the human immunodeficiency virus. Ophthalmology 102:1319 1324. 18. Sansonno, D., A. Carbone, V. De Re, and F. Dammacco. 2007. Hepatitis C virus infection, cryoglobulinaemia, and beyond. Rheumatology (Oxford) 46:572 578. 19. Arbuckle, M.R., M.T McClain, M.V. Rubertone, R.H. Scofield, G.J. Dennis, J.A. James, and J.B. Harley. 2003. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349:1526 1533. 20. Salomonsson, S., L. Ottosson, P. Safsten, D. Hof, H. Brauner, M. Sunnerhagen, J. Raats, and M. Wahren Herlenius. 2004. Cloning and characterization of two human Ro52 specific monoclonal autoantibodies directed towards a domain associated with congenital heart block. J Autoimmun 22:167 177. 21. von Muhlen, C.A., and E.M. Tan. 1995. Autoantibodies in the diagnosis of systemic rheumatic diseases. Semin Arthritis Rheum 24:323 358. 22. Wolin, S.L., and K.M. Reinisch. 2006. The Ro 60 kDa autoantigen comes into focus: interpreting epitope mapping experime nts on the basis of structure. Autoimmun Rev 5:367 372. 23. Chen, X., and S.L. Wolin. 2004. The Ro 60 kDa autoantigen: insights into cellular function and role in autoimmunity. J Mol Med 82:232 239. 24. Lyons, R., S. Narain, C. Nichols, M. Satoh, and W.H Reeves. 2005. Effective use of autoantibody tests in the diagnosis of systemic autoimmune disease. Ann N Y Acad Sci 1050:217 228.
56 25. Fabini, G., S.A. Rutjes, C. Zimmermann, G.J. Pruijn, and G. Steiner. 2000. Analysis of the molecular composition of Ro r ibonucleoprotein complexes. Identification of novel Y RNA binding proteins. Eur J Biochem 267:2778 2789. 26. Rinke, J., and J.A. Steitz. 1982. Precursor molecules of both human 5S ribosomal RNA and transfer RNAs are bound by a cellular protein reactive wi th anti La lupus antibodies. Cell 29:149 159. 27. Xiao, Q., T.V. Sharp, I.W. Jeffrey, M.C. James, G.J. Pruijn, W.J. van Venrooij, and M.J. Clemens. 1994. The La antigen inhibits the activation of the interferon inducible protein kinase PKR by sequestering and unwinding double stranded RNA. Nucleic Acids Res 22:2512 2518. 28. Chan, E.K., J.C. Hamel, J.P. Buyon, and E.M. Tan. 1991. Molecular definition and sequence motifs of the 52 kD component of human SS A/Ro autoantigen. J Clin Invest 87:68 76. 29. Love ring, R., I.M. Hanson, K.L. Borden, S. Martin, N.J. O'Reilly, G.I. Evan, D. Rahman, D.J. Pappin, J. Trowsdale, and P.S. Freemont. 1993. Identification and preliminary characterization of a protein motif related to the zinc finger. Proc Natl Acad Sci U S A 90:2112 2116. 30. Landschulz, W.H., P.F. Johnson, and S.L. McKnight. 1988. The leucine zipper: a hypothetical structure common to a new class of DNA binding proteins. Science 240:1759 1764. 31. Espinosa, A., W. Zhou, M. Ek, M. Hedlund, S. Brauner, K. Pop ovic, L. Horvath, T. Wallerskog, M. Oukka, F. Nyberg, V.K. Kuchroo, and M. Wahren Herlenius. 2006. The Sjogren's syndrome associated autoantigen Ro52 is an E3 ligase that regulates proliferation and cell death. J Immunol 176:6277 6285. 32. Kong, H.J., D.E Anderson, C.H. Lee, M.K. Jang, T. Tamura, P. Tailor, H.K. Cho, J. Cheong, H. Xiong, H.C. Morse, 3rd, and K. Ozato. 2007. Cutting Edge: Autoantigen Ro52 Is an Interferon Inducible E3 Ligase That Ubiquitinates IRF 8 and Enhances Cytokine Expression in Macr ophages. J Immunol 179:26 30. 33. Markusse, H.M., H.G. Otten, T.M. Vroom, T.J. Smeets, N. Fokkens, and F.C. Breedveld. 1993. Rheumatoid factor isotypes in serum and salivary fluid of patients with primary Sjogren's syndrome. Clin Immunol Immunopathol 66:2 6 32. 34. Luppi, M., G. Longo, M.G. Ferrari, L. Ferrara, R. Marasca, P. Barozzi, M. Morselli, G. Emilia, and G. Torelli. 1996. Additional neoplasms and HCV infection in low grade lymphoma of MALT type. Br J Haematol 94:373 375.
57 35. Randen, I., O.J. Mellb ye, O. Forre, and J.B. Natvig. 1995. The identification of germinal centres and follicular dendritic cell networks in rheumatoid synovial tissue. Scand J Immunol 41:481 486. 36. Williams, R.C., Jr., O.J. Mellbye, and G. Kronvall. 1972. Anti gamma globulin s and chronic infection: comparative studies of the immune response to various bacteria and gamma globulin preparations. Infect Immun 6:316 323. 37. Radoux, V., P.P. Chen, J.A. Sorge, and D.A. Carson. 1986. A conserved human germline V kappa gene directly encodes rheumatoid factor light chains. J Exp Med 164:2119 2124. 38. Carson, D.A., P.P. Chen, T.J. Kipps, V. Radoux, F.R. Jirik, R.D. Goldfien, R.I. Fox, G.J. Silverman, and S. Fong. 1987. Idiotypic and genetic studies of human rheumatoid factors. Arthri tis Rheum 30:1321 1325. 39. Deacon, E.M., J.B. Matthews, A.J. Potts, J. Hamburger, R.A. Mageed, and R. Jefferis. 1991. Expression of rheumatoid factor associated cross reactive idiotopes by glandular B cells in Sjogren's syndrome. Clin Exp Immunol 83:280 285. 40. Elagib, K.E., M. Borretzen, K.M. Thompson, and J.B. Natvig. 1999. Light chain variable (VL) sequences of rheumatoid factors (RF) in patients with primary Sjogren's syndrome (pSS): moderate contribution of somatic hypermutation. Scand J Immunol 50 :492 498. 41. Dawson, L.J., J. Stanbury, N. Venn, B. Hasdimir, S.N. Rogers, and P.M. Smith. 2006. Antimuscarinic antibodies in primary Sjogren's syndrome reversibly inhibit the mechanism of fluid secretion by human submandibular salivary acinar cells. Art hritis Rheum 54:1165 1173. 42. Robinson, C.P., J. Brayer, S. Yamachika, T.R. Esch, A.B. Peck, C.A. Stewart, E. Peen, R. Jonsson, and M.G. Humphreys Beher. 1998. Transfer of human serum IgG to nonobese diabetic Igmu null mice reveals a role for autoantibod ies in the loss of secretory function of exocrine tissues in Sjogren's syndrome. Proc Natl Acad Sci U S A 95:7538 7543. 43. Nguyen, K.H., J. Brayer, S. Cha, S. Diggs, U. Yasunari, G. Hilal, A.B. Peck, and M.G. Humphreys Beher. 2000. Evidence for antimusca rinic acetylcholine receptor antibody mediated secretory dysfunction in nod mice. Arthritis Rheum 43:2297 2306. 44. Delporte, C., and S. Steinfeld. 2006. Distribution and roles of aquaporins in salivary glands. Biochim Biophys Acta 1758:1061 1070. 45. Ha lse, A., P. Tengner, M. Wahren Herlenius, H. Haga, and R. Jonsson. 1999. Increased frequency of cells secreting interleukin 6 and interleukin 10 in peripheral blood of patients with primary Sjogren's syndrome. Scand J Immunol 49:533 538. 46. Hansen, A., K Reiter, A. Pruss, C. Loddenkemper, O. Kaufmann, A.M. Jacobi, J. Scholze, P.E. Lipsky, and T. Dorner. 2006. Dissemination of a Sjogren's syndrome
58 associated extranodal marginal zone B cell lymphoma: circulating lymphoma cells and invariant mutation patter n of nodal Ig heavy and light chain variable region gene rearrangements. Arthritis Rheum 54:127 137. 47. Salomonsson, S., and M. Wahren Herlenius. 2003. Local production of Ro/SSA and La/SSB autoantibodies in the target organ coincides with high levels o f circulating antibodies in sera of patients with Sjogren's syndrome. Scand J Rheumatol 32:79 82. 48. Tengner, P., A.K. Halse, H.J. Haga, R. Jonsson, and M. Wahren Herlenius. 1998. Detection of anti Ro/SSA and anti La/SSB autoantibody producing cells in s alivary glands from patients with Sjogren's syndrome. Arthritis Rheum 41:2238 2248. 49. Jacobi, A.M., A. Hansen, O. Kaufmann, A. Pruss, G.R. Burmester, P.E. Lipsky, and T. Dorner. 2002. Analysis of immunoglobulin light chain rearrangements in the salivary gland and blood of a patient with Sjogren's syndrome. Arthritis Res 4:R4. 50. Rosen, A., and L. Casciola Rosen. 2004. Altered autoantigen structure in Sjogren's syndrome: implications for the pathogenesis of autoimmune tissue damage. Crit Rev Oral Biol M ed 15:156 164. 51. Fadok, V.A. 1999. Clearance: the last and often forgotten stage of apoptosis. J Mammary Gland Biol Neoplasia 4:203 211. 52. Tsunawaki, S., S. Nakamura, Y. Ohyama, M. Sasaki, A. Ikebe Hiroki, A. Hiraki, T. Kadena, E. Kawamura, W. Kumama ru, M. Shinohara, and K. Shirasuna. 2002. Possible function of salivary gland epithelial cells as nonprofessional antigen presenting cells in the development of Sjogren's syndrome. J Rheumatol 29:1884 1896. 53. Dong, X., K.J. Hamilton, M. Satoh, J. Wang, and W.H. Reeves. 1994. Initiation of autoimmunity to the p53 tumor suppressor protein by complexes of p53 and SV40 large T antigen. J Exp Med 179:1243 1252. 54. Chetty, R. 1998. HIV associated lymphoepithelial cysts and lesions: morphological and immunohi stochemical study of the lymphoid cells. Histopathology 33:222 229. 55. Fox, R.I., Luppi, M., Kang, H., Pisa, P. 2004. Reactivation of Epstein Barr virus in Sjgren's syndrome. Springer Seminars in Immunopathology 13:217 231. 56. Davidoff, A.M., J.D. Igl ehart, and J.R. Marks. 1992. Immune response to p53 is dependent upon p53/HSP70 complexes in breast cancers. Proc Natl Acad Sci U S A 89:3439 3442. 57. Disis, M.L., J.W. Smith, A.E. Murphy, W. Chen, and M.A. Cheever. 1994. In vitro generation of human cyt olytic T cells specific for peptides derived from the HER 2/neu protooncogene protein. Cancer Res 54:1071 1076.
59 58. Chen, W., D.J. Peace, D.K. Rovira, S.G. You, and M.A. Cheever. 1992. T cell immunity to the joining region of p210BCR ABL protein. Proc Natl Acad Sci U S A 89:1468 1472. 59. Borovecki, A., P. Korac, R.A. Ventura, M.M. Perisa, A.H. Banham, and M. Dominis. 2007. MALT1, BCL10 and FOXP1 in salivary gland mucosa associated lymphoid tissue lymphomas. Pathol Int 57:47 51. 60. Kim, H.J., V. Krenn, G Steinhauser, and C. Berek. 1999. Plasma cell development in synovial germinal centers in patients with rheumatoid and reactive arthritis. J Immunol 162:3053 3062. 61. Schroder, A.E., A. Greiner, C. Seyfert, and C. Berek. 1996. Differentiation of B cells in the nonlymphoid tissue of the synovial membrane of patients with rheumatoid arthritis. Proc Natl Acad Sci U S A 93:221 225. 62. Aloisi, F., and R. Pujol Borrell. 2006. Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 6:205 217. 6 3. Prochorec Sobieszek, M., T. Wagner, M. Loukas, H. Chwalinska Sadowska, and M. Olesinska. 2004. Histopathological and immunohistochemical analysis of lymphoid follicles in labial salivary glands in primary and secondary Sjogren's syndrome. Med Sci Monit 10:BR115 121. 64. Amft, N., S.J. Curnow, D. Scheel Toellner, A. Devadas, J. Oates, J. Crocker, J. Hamburger, J. Ainsworth, J. Mathews, M. Salmon, S.J. Bowman, and C.D. Buckley. 2001. Ectopic expression of the B cell attracting chemokine BCA 1 (CXCL13) on endothelial cells and within lymphoid follicles contributes to the establishment of germinal center like structures in Sjogren's syndrome. Arthritis Rheum 44:2633 2641. 65. Barone, F., M. Bombardieri, A. Manzo, M.C. Blades, P.R. Morgan, S.J. Challacombe, G. Valesini, and C. Pitzalis. 2005. Association of CXCL13 and CCL21 expression with the progressive organization of lymphoid like structures in Sjogren's syndrome. Arthritis Rheum 52:1773 1784. 66. Salomonsson, S., M.V. Jonsson, K. Skarstein, K.A. Broksta d, P. Hjelmstrom, M. Wahren Herlenius, and R. Jonsson. 2003. Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjogren's syndrome. Arthritis Rheum 48:3187 3201. 67. Armengol, M.P., M. Juan A. Lucas Martin, M.T. Fernandez Figueras, D. Jaraquemada, T. Gallart, and R. Pujol Borrell. 2001. Thyroid autoimmune disease: demonstration of thyroid antigen specific B cells and recombination activating gene expression in chemokine containing active in trathyroidal germinal centers. Am J Pathol 159:861 873. 68. Hansen, A., M. Odendahl, K. Reiter, A.M. Jacobi, E. Feist, J. Scholze, G.R. Burmester, P.E. Lipsky, and T. Dorner. 2002. Diminished peripheral blood memory B cells and
60 accumulation of memory B ce lls in the salivary glands of patients with Sjogren's syndrome. Arthritis Rheum 46:2160 2171. 69. Szodoray, P., P. Alex, M.V. Jonsson, N. Knowlton, I. Dozmorov, B. Nakken, N. Delaleu, R. Jonsson, and M. Centola. 2005. Distinct profiles of Sjogren's syndro me patients with ectopic salivary gland germinal centers revealed by serum cytokines and BAFF. Clin Immunol 117:168 176. 70. Bahler, D.W., and S.H. Swerdlow. 1998. Clonal salivary gland infiltrates associated with myoepithelial sialadenitis (Sjogren's syn drome) begin as nonmalignant antigen selected expansions. Blood 91:1864 1872. 71. Sagaert, X., B. Sprangers, and C. De Wolf Peeters. 2007. The dynamics of the B follicle: understanding the normal counterpart of B cell derived malignancies. Leukemia 21:137 8 1386. 72. Kelaidi, C., F. Rollot, S. Park, M. Tulliez, B. Christoforov, Y. Calmus, P. Podevin, D. Bouscary, P. Sogni, P. Blanche, and F. Dreyfus. 2004. Response to antiviral treatment in hepatitis C virus associated marginal zone lymphomas. Leukemia 18: 1711 1716. 73. Suarez, F., O. Lortholary, O. Hermine, and M. Lecuit. 2006. Infection associated lymphomas derived from marginal zone B cells: a model of antigen driven lymphoproliferation. Blood 107:3034 3044. 74. Wilkie, N.M., R.P. Eglin, P.G. Sanders, and J.B. Clements. 1980. The association of herpes simplex virus with squamous carcinoma of the cervix, and studies of the virus thymidine kinase gene. Proc R Soc Lond B Biol Sci 210:411 421. 75. Royer, B., D. Cazals Hatem, J. Sibilia, F. Agbalika, J.M. C ayuela, T. Soussi, F. Maloisel, J.P. Clauvel, J.C. Brouet, and X. Mariette. 1997. Lymphomas in patients with Sjogren's syndrome are marginal zone B cell neoplasms, arise in diverse extranodal and nodal sites, and are not associated with viruses. Blood 90:7 66 775. 76. Zignego, A.L., C. Giannini, and C. Ferri. 2007. Hepatitis C virus related lymphoproliferative disorders: an overview. World J Gastroenterol 13:2467 2478. 77. Chan, C.H., K.G. Hadlock, S.K. Foung, and S. Levy. 2001. V(H)1 69 gene is preferentia lly used by hepatitis C virus associated B cell lymphomas and by normal B cells responding to the E2 viral antigen. Blood 97:1023 1026. 78. Miklos, J.A., S.H. Swerdlow, and D.W. Bahler. 2000. Salivary gland mucosa associated lymphoid tissue lymphoma immun oglobulin V(H) genes show frequent use of V1 69 with distinctive CDR3 features. Blood 95:3878 3884. 79. Bahler, D.W., J.A. Miklos, and S.H. Swerdlow. 1997. Ongoing Ig gene hypermutation in salivary gland mucosa associated lymphoid tissue type lymphomas. B lood 89:3335 3344.
61 80. Kato, K., K. Ohshima, S. Shiokawa, T. Shibata, J. Suzumiya, and M. Kikuchi. 2002. Rearrangement of immunoglobulin heavy and light chains and VH family in thyroid and salivary gland lymphomas. Pathol Int 52:747 754. 81. Montalban, C. A. Manzanal, D. Boixeda, C. Redondo, and C. Bellas. 1995. Treatment of low grade gastric MALT lymphoma with Helicobacter pylori eradication. Lancet 345:798 799. 82. Lenze, D., E. Berg, R. Volkmer Engert, A.A. Weiser, A. Greiner, C. Knorr Wittmann, I. An agnostopoulos, H. Stein, and M. Hummel. 2006. Influence of antigen on the development of MALT lymphoma. Blood 107:1141 1148. 83. Hussell, T., P.G. Isaacson, J.E. Crabtree, and J. Spencer. 1996. Helicobacter pylori specific tumour infiltrating T cells prov ide contact dependent help for the growth of malignant B cells in low grade gastric lymphoma of mucosa associated lymphoid tissue. J Pathol 178:122 127. 84. Quinn, E.R., C.H. Chan, K.G. Hadlock, S.K. Foung, M. Flint, and S. Levy. 2001. The B cell receptor of a hepatitis C virus (HCV) associated non Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis. Blood 98:3745 3749. 85. Shokri, F., R.A. Mageed, B.R. Maziak, N. Talal, N. Amos, B.D. Williams, and R. Jefferis. 1993. L ymphoproliferation in primary Sjogren's syndrome. Evidence of selective expansion of a B cell subset characterized by the expression of cross reactive idiotypes. Arthritis Rheum 36:1128 1136. 86. Bende, R.J., W.M. Aarts, R.G. Riedl, D. de Jong, S.T. Pals, and C.J. van Noesel. 2005. Among B cell non Hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity. J Exp Med 201:1229 1241. 87. Reeves WH, S.M., Lyons R, Nichols C, Narain S. 2006. Detection of autoantibodies against proteins and ribonucleoproteins by double immunodiffusion and immunoprecipitation. ASM Press, Washington, DC. 1007 1018 pp. 88. Yamasaki, Y., H. Yamada, T. Nozaki, J. Akaogi, C. Nichols, R. Lyons, A.C. Loy, E.K. Chan, W.H. Reeve s, and M. Satoh. 2006. Unusually high frequency of autoantibodies to PL 7 associated with milder muscle disease in Japanese patients with polymyositis/dermatomyositis. Arthritis Rheum 54:2004 2009. 89. Matolcsy, A., E.J. Schattner, D.M. Knowles, and P. Ca sali. 1999. Clonal evolution of B cells in transformation from low to high grade lymphoma. Eur J Immunol 29:1253 1264. 90. Wardemann, H., S. Yurasov, A. Schaefer, J.W. Young, E. Meffre, and M.C. Nussenzweig. 2003. Predominant autoantibody production by e arly human B cell precursors. Science 301:1374 1377.
62 91. Herve, M., K. Xu, Y.S. Ng, H. Wardemann, E. Albesiano, B.T. Messmer, N. Chiorazzi, and E. Meffre. 2005. Unmutated and mutated chronic lymphocytic leukemias derive from self reactive B cell precursors despite expressing different antibody reactivity. J Clin Invest 115:1636 1643. 92. Braylan, R.C. 1993. Flow cytometric DNA analysis in the diagnosis and prognosis of lymphoma. Am J Clin Pathol 99:374 380. 93. Braylan, R.C., N.A. Benson, and J. Iturraspe 1993. Analysis of lymphomas by flow cytometry. Current and emerging strategies. Ann N Y Acad Sci 677:364 378. 94. Schable, K.F., and H.G. Zachau. 1993. The variable genes of the human immunoglobulin kappa locus. Biol Chem Hoppe Seyler 374:1001 1022. 95 Miyasaka, N., K. Yamaoka, M. Tateishi, K. Nishioka, and K. Yamamoto. 1989. Possible involvement of Epstein Barr virus (EBV) in polyclonal B cell activation in Sjogren's syndrome. J Autoimmun 2:427 432. 96. Tateishi, M., I. Saito, K. Yamamoto, and N. Miy asaka. 1993. Spontaneous production of Epstein Barr virus by B lymphoblastoid cell lines obtained from patients with Sjogren's syndrome. Possible involvement of a novel strain of Epstein Barr virus in disease pathogenesis. Arthritis Rheum 36:827 835. 97. Isaacson, P.G., and M.Q. Du. 2004. MALT lymphoma: from morphology to molecules. Nat Rev Cancer 4:644 653. 98. Du, M., T.C. Diss, C. Xu, H. Peng, P.G. Isaacson, and L. Pan. 1996. Ongoing mutation in MALT lymphoma immunoglobulin gene suggests that antigen s timulation plays a role in the clonal expansion. Leukemia 10:1190 1197. 99. Gasparotto, D., S. De Vita, V. De Re, A. Marzotto, G. De Marchi, C.A. Scott, A. Gloghini, G. Ferraccioli, and M. Boiocchi. 2003. Extrasalivary lymphoma development in Sjogren's sy ndrome: clonal evolution from parotid gland lymphoproliferation and role of local triggering. Arthritis Rheum 48:3181 3186. 100. Stott, D.I., F. Hiepe, M. Hummel, G. Steinhauser, and C. Berek. 1998. Antigen driven clonal proliferation of B cells within th e target tissue of an autoimmune disease. The salivary glands of patients with Sjogren's syndrome. J Clin Invest 102:938 946. 101. Wotherspoon, A.C., C. Doglioni, T.C. Diss, L. Pan, A. Moschini, M. de Boni, and P.G. Isaacson. 1993. Regression of primary l ow grade B cell gastric lymphoma of mucosa associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 342:575 577.
63 102. Martin, T., J.C. Weber, H. Levallois, N. Labouret, A. Soley, S. Koenig, A.S. Korganow, and J.L. Pasquali. 2000. S alivary gland lymphomas in patients with Sjogren's syndrome may frequently develop from rheumatoid factor B cells. Arthritis Rheum 43:908 916. 103. Zouali, M., and J. Theze. 1991. Probing VH gene family utilization in human peripheral B cells by in situ h ybridization. J Immunol 146:2855 2864. 104. Tierens, A., J. Delabie, S. Pittaluga, A. Driessen, and C. DeWolf Peeters. 1998. Mutation analysis of the rearranged immunoglobulin heavy chain genes of marginal zone cell lymphomas indicates an origin from diff erent marginal zone B lymphocyte subsets. Blood 91:2381 2386. 105. Abderrazik, M., M. Moynier, and J. Brochier. 1995. Preferential use of the VHIII immunoglobulin gene family for the synthesis of rheumatoid factors. Adv Exp Med Biol 371B:1207 1212. 106. Ermel, R.W., T.P. Kenny, A. Wong, P.P. Chen, W. Malyj, and D.L. Robbins. 1997. Analysis of the molecular basis of synovial rheumatoid factors in rheumatoid arthritis. Clin Immunol Immunopathol 84:307 317. 107. Horsfall, A.C., and D.A. Isenberg. 1988. Idio types and autoimmunity: a review of their role in human disease. J Autoimmun 1:7 30. 108. Hjelmstrom, P. 2001. Lymphoid neogenesis: de novo formation of lymphoid tissue in chronic inflammation through expression of homing chemokines. J Leukoc Biol 69:331 339. 109. Imai, H., K. Kiyosawa, E.K. Chan, and E.M. Tan. 1993. Autoantibodies in viral hepatitis related hepatocellular carcinoma. Intervirology 35:73 85. 110. Zhang, J.Y., E.K. Chan, X.X. Peng, and E.M. Tan. 1999. A novel cytoplasmic protein with RNA b inding motifs is an autoantigen in human hepatocellular carcinoma. J Exp Med 189:1101 1110. 111. Dalmau, J., F. Graus, M.K. Rosenblum, and J.B. Posner. 1992. Anti Hu -associated paraneoplastic encephalomyelitis/sensory neuronopathy. A clinical study of 71 patients. Medicine (Baltimore) 71:59 72. 112. Lee, C.H., M. Melchers, H. Wang, T.A. Torrey, R. Slota, C.F. Qi, J.Y. Kim, P. Lugar, H.J. Kong, L. Farrington, B. van der Zouwen, J.X. Zhou, V. Lougaris, P.E. Lipsky, A.C. Grammer, and H.C. Morse, 3rd. 2006. Regulation of the germinal center gene program by interferon (IFN) regulatory factor 8/IFN consensus sequence binding protein. J Exp Med 203:63 72. 113. Reeves, W.H. 2001. Tumor immunity and autoimmunity: a case of Dr. Jekyll and Mr. Hyde. Clin Immunol 10 0:129 133.
64 114. Kishimoto, T., S. Akira, M. Narazaki, and T. Taga. 1995. Interleukin 6 family of cytokines and gp130. Blood 86:1243 1254. 115. Jourdan, M., R. Bataille, J. Seguin, X.G. Zhang, P.A. Chaptal, and B. Klein. 1990. Constitutive production of in terleukin 6 and immunologic features in cardiac myxomas. Arthritis Rheum 33:398 402. 116. Airoldi, I., R. Guglielmino, F. Ghiotto, A. Corcione, P. Facchetti, M. Truini, and V. Pistoia. 2001. Cytokine gene expression in neoplastic B cells from human mantle cell, follicular, and marginal zone lymphomas and in their postulated normal counterparts. Cancer Res 61:1285 1290. 117. Gronbaek, K., P.T. Straten, E. Ralfkiaer, V. Ahrenkiel, M.K. Andersen, N.E. Hansen, J. Zeuthen, K. Hou Jensen, and P. Guldberg. 1998. Somatic Fas mutations in non Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood 92:3018 3024. 118. Nagata, S. 1998. Human autoimmune lymphoproliferative syndrome, a defect in the apoptosis inducing Fas receptor: a lesson from the mouse model. J Hum Genet 43:2 8. 119. Wu, X., C. Molinaro, N. Johnson, and C.A. Casiano. 2001. Secondary necrosis is a source of proteolytically modified forms of specific intracellular autoantigens: implications for systemic autoimmunity. Arthritis Rheum 44:2642 2652.
65 BIOGRAPHICAL SKETCH Robert Capel Lyons was born in Albany, NY on October 29, 1982. He lived and attended school in Albany during his youth, until he moved to Port St. Lucie, FL H e attended and graduated from Port St. Lucie High School in 2000. After high school, Robert attended the University of Florida in Gainesville, where he obtained a Bachelor of Science in microbiology and cell science with a minor in chemistry. During this time, he worked as a student researcher in the D epartment of Medicine, Division of Rheumatology and Clinical Immunology under Dr. Westley H. Reeves. While a senior at UF Robert earned an EMT certification from Sante Fe Community College, graduating at the top of his EMT class Upon graduation, Rober t became shift leader for Alachua County Fire Rescue. Robert was then admitted to He continued the research that he started as an undergraduate under the direction of Dr. Westley H. Reeves. H patient with lymphoma. After completing his M.S., Robert will enter medical school at the University of Florida. Upon graduation, Robert will apply for and complete a reside ncy for board certification. His ultimate professional goals include becoming an academic physician with an emphasis on teaching.